ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) EBIT : $-6.0 Mil (TTM As of Sep. 2016)

ARIAD Pharmaceuticals EBIT Chart

ARIAD Pharmaceuticals Annual Data
	Trend	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15
EBIT		Get a 7-Day Free Trial					-123.37	-220.67	-273.57	-153.90	-216.40

ARIAD Pharmaceuticals Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
EBIT	Get a 7-Day Free Trial															-56.07	-52.69	-48.59	117.00	-21.74

Competitive Comparison of ARIAD Pharmaceuticals's EBIT

For the Biotechnology subindustry, ARIAD Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARIAD Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ARIAD Pharmaceuticals's EV-to-EBIT falls into.

ARIAD Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARIAD Pharmaceuticals  (NAS:ARIA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ARIAD Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2016 is calculated as:

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

ARIAD Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ARIAD Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARIAD Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description